Data showed that either cisplatin-resistant cells or serum-free cultured cells expressed statistically higher expression levels of CD133 and CD44, which have been confirmed as contributors in migration and aggregation of cancer cells and cancer development and hence have been broadly accepted as general cancer stem cell markers in many types of malignant tumors, including cervical carcinoma [13]. This evidence concerns the gene PROM1 and cervical carcinoma.